- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Ivonescimab, Stereotactic Radiosurgery
- Drug · Radiation
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 289–312
of 3,461
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Sapanisertib
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Esophageal Cancer, Gastric Cancer
- Interventions
- G17DT Immunogen, cisplatin, fluorouracil
- Biological · Drug
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2002
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Locally Advanced Cervical Carcinoma, Locally Advanced Endometrial Carcinoma, Locally Advanced Gastric Adenocarcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Locally Advanced Head and Neck Squamous Cell Carcinoma, Locally Advanced Hepatocellular Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Malignant Solid Neoplasm, Locally Advanced Melanoma, Locally Advanced Merkel Cell Carcinoma, Locally Advanced Renal Cell Carcinoma, Locally Advanced Skin Squamous Cell Carcinoma, Locally Advanced Triple-Negative Breast Carcinoma, Locally Advanced Unresectable Breast Carcinoma, Locally Advanced Unresectable Cervical Carcinoma, Locally Advanced Unresectable Gastric Adenocarcinoma, Locally Advanced Unresectable Gastroesophageal Junction Adenocarcinoma, Locally Advanced Unresectable Renal Cell Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Cervical Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hepatocellular Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Merkel Cell Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Metastatic Urothelial Carcinoma, Skin Squamous Cell Carcinoma, Stage III Cervical Cancer AJCC v8, Stage III Hepatocellular Carcinoma AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage IIIA Cervical Cancer AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIA Uterine Corpus Cancer AJCC v8, Stage IIIB Cervical Cancer AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIB Uterine Corpus Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IIIC Uterine Corpus Cancer AJCC v8, Stage IIIC1 Uterine Corpus Cancer AJCC v8, Stage IIIC2 Uterine Corpus Cancer AJCC v8, Stage IV Cervical Cancer AJCC v8, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IVA Cervical Cancer AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVA Uterine Corpus Cancer AJCC v8, Stage IVB Cervical Cancer AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Stage IVB Lung Cancer AJCC v8, Stage IVB Uterine Corpus Cancer AJCC v8, Triple-Negative Breast Carcinoma, Unresectable Cervical Carcinoma, Unresectable Endometrial Carcinoma, Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Unresectable Head and Neck Squamous Cell Carcinoma, Unresectable Hepatocellular Carcinoma, Unresectable Lung Non-Small Cell Carcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Melanoma, Unresectable Merkel Cell Carcinoma, Unresectable Renal Cell Carcinoma, Unresectable Skin Squamous Cell Carcinoma, Unresectable Triple-Negative Breast Carcinoma, Unresectable Urothelial Carcinoma, Breast Adenocarcinoma, Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Invasive Breast Lobular Carcinoma
- Interventions
- Cyclophosphamide, Neoantigen Peptide Vaccine, Pembrolizumab, Sargramostim, Biospecimen Collection, Biopsy, Computed Tomography, Magnetic Resonance Imaging
- Drug · Biological · Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Gastroparesis
- Interventions
- Gastric Electrical Stimulation (GES) System
- Device
- Lead sponsor
- Texas Tech University Health Sciences Center, El Paso
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- El Paso, Texas
- Conditions
- Osteogenesis Imperfecta Type II, Osteogenesis Imperfecta Type III
- Interventions
- Mesenchymal Stromal Cells
- Biological
- Lead sponsor
- Nationwide Children's Hospital
- Other
- Eligibility
- Up to 19 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Olaparib
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 11
- States / cities
- Orange, California • New Haven, Connecticut • Coral Gables, Florida + 8 more
- Conditions
- Advanced Hepatocellular Carcinoma, Cirrhosis, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8
- Interventions
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Multigated Acquisition Scan, Zanzalintinib
- Procedure · Drug
- Lead sponsor
- Devalingam Mahalingam
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Diabetes Mellitus, Type 2, Diabetes Mellitus, Adult-Onset, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Noninsulin Dependent, Diabetes Mellitus, Type II
- Interventions
- Technology Intensified
- Behavioral
- Lead sponsor
- State University of New York at Buffalo
- Other
- Eligibility
- 21 Years to 100 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2026
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Mucopolysaccharidosis I, Hurler Syndrome
- Interventions
- Stem Cell Transplant, Laronidase ERT
- Procedure · Drug
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 7 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2012
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Malignant Neoplasm
- Interventions
- Educational Intervention, Survey Administration
- Other
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 2
- States / cities
- Portland, Oregon
- Conditions
- Alveolar Childhood Rhabdomyosarcoma, Embryonal Childhood Rhabdomyosarcoma, Embryonal-botryoid Childhood Rhabdomyosarcoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Rhabdomyosarcoma
- Interventions
- vincristine sulfate, irinotecan hydrochloride, cyclophosphamide, doxorubicin hydrochloride, ifosfamide, etoposide, tirapazamine, filgrastim, sargramostim, pharmacological study, pharmacogenomic studies, laboratory biomarker analysis
- Drug · Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 20 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 1
- States / cities
- Arcadia, California
- Conditions
- Acral Lentiginous Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Mucosal Melanoma
- Interventions
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Pembrolizumab, Therapeutic Conventional Surgery
- Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 313 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 815
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 511 more
- Conditions
- Peripheral Artery Disease
- Interventions
- cocoa flavanols, placebo
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Minneapolis, Minnesota
- Conditions
- HER2-Positive Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
- Interventions
- Aromatase Inhibition Therapy, Carboplatin, Cytology Specimen Collection Procedure, Docetaxel, Goserelin Acetate, Laboratory Biomarker Analysis, Pertuzumab, Quality-of-Life Assessment, Therapeutic Conventional Surgery, Trastuzumab, Whole Breast Irradiation
- Drug · Other · Biological + 2 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 315 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2025
- U.S. locations
- 731
- States / cities
- Fairbanks, Alaska • Hot Springs, Arkansas • Anaheim, California + 466 more
- Conditions
- Alcoholism
- Interventions
- Stand Down app, Peer-Supported Stand Down, Usual Care
- Behavioral · Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- Not listed
- Enrollment
- 234 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 2
- States / cities
- Palo Alto, California • Syracuse, New York
- Conditions
- Extensive-Stage Small Cell Lung Cancer
- Interventions
- sunitinib
- Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Pancreatic Adenocarcinoma, Liver Metastases
- Interventions
- Floxuridine (FUDR), Hepatic Artery Infusion Pump, Heparinized Saline
- Drug · Device
- Lead sponsor
- Corewell Health West
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 1
- States / cities
- Grand Rapids, Michigan
- Conditions
- Metastatic Uveal Melanoma
- Interventions
- Defactinib Hydrochloride, Raf/MEK Inhibitor VS-6766, Biopsy
- Drug · Procedure
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Esophageal Cancer, Gastric Cancer
- Interventions
- epirubicin, cisplatin, capecitabine, bevacizumab, docetaxel and irinotecan
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 5
- States / cities
- Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Locally Advanced Laryngeal Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma
- Interventions
- Toripalimab, Carboplatin, Cisplatin, Paclitaxel, Radiation Therapy
- Drug · Radiation
- Lead sponsor
- Matthew Spector
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Dementia
- Interventions
- Tailored Activity Program, Home Safety and Education Program
- Behavioral · Other
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Epithelial Ovarian Cancer
- Interventions
- CC-486, Pembrolizumab
- Drug · Biological
- Lead sponsor
- Translational Research in Oncology
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Baltimore, Maryland • Minneapolis, Minnesota + 1 more
- Conditions
- Lumbar Spinal Stenosis
- Interventions
- lumbar decompression
- Procedure
- Lead sponsor
- Vertos Medical, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 8
- States / cities
- Merritt Island, Florida • Baltimore, Maryland • Festus, Missouri + 5 more